Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new ...

Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Natera NTRA recently announced that Signatera has received PMDA approval in Japan for use in colorectal cancer (CRC) patients ...

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...

The FDA's Breakthrough Devices Program accelerates access to promising medical devices for serious conditions, ensuring safety and effectiveness through a rigorous review process. Haystack MRD test ...

Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers. Minimal residual disease, or MRD, ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...

Earlier blood-test detection could help identify pancreatic cancer patients who need more aggressive treatment, an expert ...